NEWSWIRETODAY Press Release & Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Agency / Source: NeonDrum Ltd

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

IVF Proven Unnecessary for Many Infertile Couples - DuoFertility Study Shows - Study demonstrates a viable non-invasive, drug-free alternative to IVF - DuoFertility.com
IVF Proven Unnecessary for Many Infertile Couples - DuoFertility Study Shows

 

NewswireTODAY - /newswire/ - Cambridge, United Kingdom, 2011/09/23 - Study demonstrates a viable non-invasive, drug-free alternative to IVF - DuoFertility.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

A new study published in European Obstetrics & Gynaecology shows that just six months using the DuoFertility monitor and service gives the same chance of pregnancy as a cycle of in-vitro fertilisation (IVF) for many infertile couples. This study demonstrates that there is a viable non-invasive, drug-free alternative to IVF for thousands of couples, with the potential to save them (and the NHS) millions of pounds each year.

The paper is the first peer-reviewed publication of clinical pregnancy rates using the new DuoFertility product and service. Lead author, Dr. Oriane Chausiaux said “The results show that for couples suffering from unexplained infertility as well as a variety of other factors, twelve months using DuoFertility yields a higher clinical pregnancy rate than a cycle of IVF.” Not only is IVF invasive for the woman and demeaning for the man, but for many couples it is a procedure needlessly costing the NHS, or the couple themselves, thousands of pounds. A typical cycle of IVF in the private sector costs £7,000 all up. By comparison the DuoFertility program offers a year of monitoring and support for £500 - and it comes with a 12-month money-back pregnancy guarantee.

The publication coincides with the 200th reported pregnancy by users of DuoFertility, which was celebrated at the weekend with a party hosted by medical personality Dr. Miriam Stoppard. Dr. Stoppard, addressing the assembled parents and parents-to-be, said "[it is] the first product or service that I have seen in this arena which truly wraps around all of the needs of the couple, from the medical monitoring, to the review of this data by experts, and then the all-important emotional support that is provided."..."The results of the scientific studies on pregnancy rate are very encouraging, but do need to be followed up with live birth rates, and I look forward to seeing further research."

The authors of the study caution that although non-invasive and drug-free, DuoFertility is not suitable for all couples. Dr. Husheer, inventor of DuoFertility explained “although DuoFertility is suitable for around 80% of infertile couples, there are some couples with medically identified conditions that prevent natural conception, such as a woman with two blocked fallopian tubes. In these cases IVF is absolutely the right thing to do, enabling conception where it was previously a physical impossibility.”

About Cambridge Temperature Concepts
Cambridge Temperature Concepts Limited (CTC) has developed a new kind of wireless physiological monitor, which measures body temperature, heat flow and movement with unprecedented resolution. The first application (DuoFertility) is in conception assistance for couples suffering infertility, however work is underway in areas as diverse as sleep quality monitoring, hypoglycemia detection, infection control and a range of veterinary applications. DuoFertility is a non-invasive, easy-to-use female fertility monitor. It is the most natural, convenient, and precise way of maximising the chances of getting pregnant.

CTC was founded by graduate students at the University of Cambridge in, winning business competitions at collegiate, university, regional and national levels prior to Angel funding. Less than 18 months later, the DuoFertility product had progressed from sheet-of-paper through medical device approvals, production prototype, Europe-wide trial, and had gained first direct-to-consumer sales.

Media Contact: Helen Dye / T: 01223 967707

Distributed by NeonDrum.com news distribution service on behalf of Cambridge Temperature Concepts.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: NeonDrum Ltd

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


IVF Proven Unnecessary for Many Infertile Couples - DuoFertility Study Shows

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Liz Hartney - NeonDrum.com 
+44(0)75 1051 8732 news[.]neondrum.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any NeonDrum Ltd securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From NeonDrum Ltd / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Ono Pharma Submits a Supplemental Application in Japan to Expand the Use of VELEXBRU® Tablets for the Treatment of Central Nervous System Involvement
Ono Pharma Announces Poster Presentation of New Clinical Data from Phase 2 Study of ONO-2808 in Multiple System Atrophy At the 7th World Parkinson Con
Ipsen Announces Late-breaking Data from First Head-to-head Study Comparing Dysport® and Botox® in Adults with Upper Limb Spasticity
Ipsen Unveils Corabotase, A First-in-class Recombinant Neuroinhibitor, RNI™ At the SCALE Symposium
SCHOTT Pharma Expands Portfolio for Sensitive Biologics with CartriQ® BioPure
Ojemda® Approved in The European Union as the First Targeted Therapy in Relapsed or Refractory Pediatric Low-grade Glioma
Ono Pharma Submits an Application for Approval of Ripretinib (DCC-2618) in Patients with Advanced Gastrointestinal Stromal Tumor in Japan
Locus FS Receives the 2026 North American Precision Fermentation Technology Innovation Leadership Recognition
Ipsen Showcases Transformative Potential of Early Immuno-oncology Pipeline At AACR
Ono Pharma Announces New Drug Discovery Collaboration with Congruence Therapeutics in the Priority Areas of Neurology and Immunology
Ono Pharma Announces Transfer of the Manufacturing and Marketing Approval Authorization for Opalmon® Tablets and Prostandin® Ointment
Ono Announces U.S. Food and Drug Administration Acceptance for Filing of New Drug Application for Tirabrutinib in Patients with Relapsed or Refractory
SCHOTT Pharma Launches EVERIC® Lyo & Amber Vials for Light-sensitive ADCs
Arbitration Tribunal Upholds Ipsen’s Termination of R&D Agreement with Galderma
New Data Reinforces Ipsen’s Commitment to Bringing Solutions and Addressing Care Gaps in Neurological Diseases At TOXINS

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Limelon Advertising, Co.

Visit  JobsWare.com





 
  ©2005-2026 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)